Efficacy and safety of human albumin combined with furosemide in acute decompensated heart failure with hepatic dysfunction.
Georgios Chalikias, Dimitrios Stakos, Adina Thomaidis et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the efficacy and safety of intravenous albumin combined with furosemide in 241 patients with acute decompensated heart failure and hepatic dysfunction. The combination therapy led to a greater improvement in symptom scores (AUC 3,767 vs 3,457 points; P < .001) and a milder increase in creatinine levels (0.07 vs 0.18 mg/dL; P = .045) compared to furosemide alone.
Key findings
- Improvement in global assessment of symptoms scores was greater in the albumin group (AUC 3,767 vs 3,457 points; P < .001).
- Creatinine levels increased less in the albumin group (0.07 vs 0.18 mg/dL; P = .045).
- Length of hospital stay was shorter in the albumin group (4 vs 5 days; P < .001).
- Incidence of worsening renal function was lower in the albumin group (25% vs 38%; P = .037).
Why it matters
Effective management of congestion in acute decompensated heart failure is crucial, especially in patients with hepatic dysfunction. This study suggests that combining intravenous albumin with furosemide may enhance symptom relief and reduce renal complications.